Pages that link to "Q33843103"
Jump to navigation
Jump to search
The following pages link to Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. (Q33843103):
Displayed 50 items.
- DNA immunization as a technology platform for monoclonal antibody induction (Q26751432) (← links)
- Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates (Q27489000) (← links)
- Effect of vaccine administration modality on immunogenicity and efficacy (Q27692376) (← links)
- Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). (Q30379200) (← links)
- Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses (Q30411149) (← links)
- Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. (Q33759392) (← links)
- Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes (Q33837215) (← links)
- Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein (Q33955745) (← links)
- Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies (Q34094476) (← links)
- The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination (Q34291205) (← links)
- A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. (Q34444535) (← links)
- Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate (Q34551010) (← links)
- Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice. (Q34797176) (← links)
- Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates (Q35076664) (← links)
- A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component (Q35076748) (← links)
- Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma. (Q35167024) (← links)
- DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers (Q35640984) (← links)
- Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs (Q35677724) (← links)
- Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy (Q35785338) (← links)
- Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine. (Q35826610) (← links)
- HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost (Q35883997) (← links)
- Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice (Q36528895) (← links)
- Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers (Q36528901) (← links)
- Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. (Q36600380) (← links)
- Combination DNA plus protein HIV vaccines. (Q36614954) (← links)
- DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China. (Q36694841) (← links)
- Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates (Q36694846) (← links)
- Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies (Q36742228) (← links)
- Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration (Q36748019) (← links)
- Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination (Q36804634) (← links)
- Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine (Q36977750) (← links)
- Polyvalent AIDS Vaccines (Q37094429) (← links)
- Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. (Q37329415) (← links)
- DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for Schistosomiasis japonica (Q37450878) (← links)
- Heterologous prime-boost vaccination. (Q37509586) (← links)
- Improvement of antibody responses by HIV envelope DNA and protein co-immunization. (Q37588371) (← links)
- Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting (Q37656791) (← links)
- The strategic use of novel smallpox vaccines in the post-eradication world. (Q37909421) (← links)
- HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. (Q38956398) (← links)
- Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects (Q39508210) (← links)
- Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes (Q41495119) (← links)
- A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design (Q41819464) (← links)
- Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice (Q41852201) (← links)
- Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines (Q41933070) (← links)
- Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers (Q42554027) (← links)
- Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera (Q45129797) (← links)
- Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses (Q45413779) (← links)
- Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. (Q45417687) (← links)
- The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients (Q47244891) (← links)
- Clostridium perfringens beta toxin DNA prime-protein boost elicits enhanced protective immune response in mice. (Q50639945) (← links)